AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$UPB

Deykin Aaron sold $5K of UPB

Deykin Aaron (Chief Medical Officer) sold 895 shares of Upstream Bio, Inc. (UPB) at $5.49 on 2026-09-16.

Original reporting
SEC EDGAR · Deykin Aaron
Published Sep 17, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UPB
Neutral
high confidence
Mentioned
$UPB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UPBNeutralLow
01

Why it matters

The transaction is routine and unlikely to affect UPB's stock price.

02

Market read

Minor insider sale with negligible market impact.

03

What to watch

Potential upcoming clinical data releases could affect insider behavior.

Relevance 3/10Novelty 4/10Timing: post-market 2026-09-16

Background

Form 4 filings disclose insider transactions; traders watch for material changes in insider holdings.

Company-level read

Ticker impact

$UPBNeutralHigh confidence
Context

Chief Medical Officer sold 895 shares for $4,913.55 on 2026-09-16, reducing his stake to 32,302 shares.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is small relative to market cap and insider holdings.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market unaffected.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings.

Key entities

  • person
    Deykin Aaron

    Chief Medical Officer of Upstream Bio, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UPB insider trading history →

Related articles

$UPBMed

Upstream Bio Reports Q3 2026 Results, Plans Phase 3 Trials for 2027

Upstream Bio reported a Q3 2026 net loss of $41.2M, up from $33.7M a year earlier, with collaboration revenue of $395K. The company has $207.4M in cash, expecting to fund operations through 2027. Upstream Bio plans to start Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, with additional trials in COPD and severe asthma expected to report data in 2027.

tradingview.com
$UPBMed

Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class eff

SEC EDGAR 8-K
$UPBMed

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress – Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-o

SEC EDGAR 8-K